Issue: July 2019
June 08, 2019
2 min watch
Save

VIDEO: Crash Course on Biologic use, Procedures in Small Bowel, Terminal Ileal Disease

Issue: July 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CLEVELAND — In this exclusive video from the Cleveland Clinic IBD Master Class, Tracy Hull, MD, section chief of inflammatory bowel disease within the Department of Colon and Rectal Surgery at Cleveland Clinic, discusses a session she moderated that focused on terminal ileal Crohn’s disease.

“There was a lot of discussion regarding the mesentery and a wide mesenteric excision for terminal ileal disease and the emerging data particularly out of Ireland and China that a wide resection could possibly delay recurrence,” she told Healio Gastroenterology and Liver Disease.

Hull noted that the panelists also discussed the use of biologics prior to surgery and mentioned that it’s probably not the biologic that physicians should be worried about when performing surgeries for IBD.

“It’s probably the steroids,” she said. “Doing surgery with a patient on biologics probably does not increase our risk of leak and sepsis.”